Nonalcoholic Fatty Liver Disease: A 7-question Quiz for Primary Care Clinicians
How prevalent is NAFLD worldwide? What is the preferred treatment? And more questions to test your NAFLD knowledge.
How to Identify & Evaluate Chronic Kidney Disease Using eGFR and UACR: In brief
Primary care clinicians are critical to screening and caring for CKD. This "In brief" slide show reviews the 2 key lab tests used to diagnose the disease.
Antiobesity Medications May Support Long-term 10% Weight Loss, Suggests New Study
ENDO 2022: Findings from the long-term, real-world study of meds for maintenance of meaningful weight loss support wider uptake of the agents, authors say.
COVID-19 Updates: US Vaccinations, Booster Doses, & Global Data as of June 14, 2022
Data from the CDC on boosters and US vaccination rates and from the Johns Hopkins COVID-19 interactive map on cases and deaths in the US and worldwide.
Patients with Diabetes Face Higher Risk for Left-sided Valvular Stenotic Lesions
A new study found patients with T1D and T2D had a greater risk for stenotic lesions, whereas risk for valvular regurgitation was lower in those with T2D.
Older Adults Today More Likely to Have Multiple Chronic Conditions than Prior Generations
Baby Boomers had more chronic health conditions and more conditions at younger ages than older adults born at the end of the Great Depression.
COVID-19 Updates: US Vaccinations, Booster Doses, & Global Data as of June 13, 2022
Novel FDA-cleared AFib History Software and Medication App Part of Newly Announced Apple Watch Update
Apple recently announced a new software release that will allow Apple Watch users access to health care-focused features and apps.
Prediabetes Independently Associated with MI, PCI, CABG: A "Wake-up Call," Study Authors Say
ENDO 2022: The large US analysis found persons with prediabetes had increased odds for heart attack of 25%, for PCI of 45%, and had nearly double the risk of having CABG.
Flash CGM Increases Time in Range for T2D Patients on Noninsulin Therapies Not at Goal HbA1c
ADA 2022: Use of flash continuous glucose monitoring in T2D patients not on insulin also reduced HbA1c and glycemic variability, a new study finds.
Healthiest and Unhealthiest Cities in America: A 2022 Ranking
WalletHub recently compared the most populated US cities to see which ones prioritize residents’ well-being. Find out which areas ranked healthiest and unhealthiest.
COVID-19 Updates: US Vaccinations, Booster Doses, & Global Data as of June 9, 2022
Continuous Glucose Monitoring Linked to Better Glycemic Control, Reduced Hospitalizations in Study of Veterans Health Administration Data
ADA 2022: Large national study found that CGM use had a positive effect on glycemic control and acute complications in T2D in the Veterans Health Administration.
Glycemic Variability with Tirzepatide Significantly Lower vs Degludec as Assessed by CGM
ADA 2022. Tirzepatide was associated with significantly greater TIR, many fewer episodes of hypoglycemia, and less glycemic excursion vs insulin degludec in SURPASS-3 CGM.
Poorly Controlled T2D Improves with Initiation of rtCGM in Primary Care
ADA 2022: Primary care patients with T2D and HbA1c >7.5% achieved as much as a 1.5% drop in HbA1c after initiating real time continuous glucose monitoring.
Study: AI-powered Intervention Led to Highest Reported Rate of T2D Remission to Date
ADA 2022: Patients with T2D who received a treatment intervention powered by artificial intelligence achieved a remission rate of more than 80%.
Semaglutide 2.4 mg Reduces 10-year Risk of Type 2 Diabetes in Patients with Overweight, Obesity
ADA 2022: Reduction in risk of progression to type 2 diabetes of 60% was seen in STEP program clinical trial participants with overweight or obesity.
Dulaglutide Improves HbA1c for Youth with Type 2 Diabetes without Change in BMI
ADA 2022: "Breakthrough" findings may help to address the unmet need for additional treatment options for young patients with type 2 diabetes.
Oral Semaglutide in Real-world Study Found Highly Effective for Uncontrolled HbA1c
ADA 2022: Oral semaglutide may be particularly effective for T2D patients with HbA1c ≥9% and prescribed more frequently for these patients by primary care clinicians.
Finerenone Cardiorenal Effects in T2D Consistent Across Baseline HbA1c, Disease Duration
ADA 2022: The protective effect of finerenone on cardiovascular and renal outcomes was not affected by initial HbA1c levels or T2D duration in analysis of data from the FIDELITY pooled cohort.
